Inc. Sells 1979 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)


The institutional investor held 60,255 shares of the consumer non-durables company at the end of 2017Q3, valued at $4.85M, up from 42,132 at the end of the previous reported quarter.

The Stock surged7.83% and closed its last trading session at $0.12. About 871,356 shares traded. It has underperformed by 38.50% the S&P500.

Alexander Medina Seaver increased its stake in United Insurance Holdings Corp (UIHC) by 255.79% based on its latest 2017Q3 regulatory filing with the SEC. The Massachusetts-based North Tide Capital Llc has invested 8.64% in the stock. The Boston Common Asset Management Llc holds 75,730 shares with $6.14 million value, up from 58,379 last quarter. The stock increased 0.46% or $0.38 during the last trading session, reaching $83.67. About 10.15 million shares traded or 24.27% up from the average. American Capital Senior Floating, Ltd. (ACSF) has risen 35.14% since January 12, 2017 and is uptrending. It has outperformed by 9.27% the S&P500.

Peak6 Investments Lp, which manages about $19.60B US Long portfolio, upped its stake in Astrazeneca Plc (Call) (NYSE:AZN) by 326,300 shares to 365,100 shares, valued at $12.37M in 2017Q3, according to the filing.

Among 23 analysts covering Lam Research Corporation (NASDAQ:LRCX), 21 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Tower International Inc had 7 analyst reports since October 20, 2015 according to SRatingsIntel. The firm earned "Hold" rating on Tuesday, July 11 by Jefferies. Morgan Stanley has "Buy" rating and $16800 target. Finally, Zacks Investment Research cut Gilead Sciences from a "hold" rating to a "sell" rating in a research report on Wednesday, December 27th. The stock of Arrow Electronics, Inc. Citigroup downgraded the stock to "Sell" rating in Monday, September 28 report. Northland Capital has "Outperform" rating and $27 target. The firm has "Hold" rating by Oppenheimer given on Wednesday, October 4.

Investors sentiment decreased to 1.16 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. (NASDAQ:MELI). 109,266 were reported by Ubs Asset Americas. Its down 4.05% from 1.15 million shares previously. Clarivest Asset Ltd Llc reported 3,567 shares stake. Cadence Bancshares Na holds 0.12% or 3,870 shares. Swedbank holds 551,711 shares. (NASDAQ:AMZN) for 4.02 million shares. Origin Asset Management Limited Liability Partnership accumulated 137,300 shares. Cleararc Capital holds 0.79% or 64,953 shares. Schroder Mgmt Group Inc holds 3.64 million shares or 0.51% of its portfolio. Silvercrest Asset Mngmt Ltd holds 44,505 shares. Cambridge Invest Research Advisors has invested 0% in Arrow Electronics, Inc.

Analysts await Lam Research Corporation (NASDAQ:LRCX) to report earnings on January, 24. They expect $1.67 EPS, down 36.74% or $0.97 from last year's $2.64 per share. (NASDAQ:GILD). Woodley Farra Manion Port Mgmt reported 2.09% of its portfolio in Gilead Sciences, Inc. About 811,897 shares traded. Amp Ltd owns 820,092 shares. Proshares Tr Ii was raised too. Gilead Sciences portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

GILD has been the subject of a number of research reports.

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 6.72 in total earnings per share. GILD's profit would be $2.18 billion giving it 11.78 P/E if the $1.67 EPS is correct.

Gilead Sciences, a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. (NASDAQ:GILD). Checchi Advisers Limited Liability Company reported 10,325 shares.

Ratings analysis reveals 60% of Gilead Sciences's analysts are positive. Bruce & Co Inc bought 143,477 shares as the company's stock rose 29.12% with the market. Credit Suisse Group reissued a "buy" rating and issued a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, December 7th. On Thursday, September 22 the stock rating was initiated by Berenberg with "Buy". The firm earned "Buy" rating on Monday, August 17 by Vetr. The company was maintained on Wednesday, June 14 by William Blair.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The firm has "Strong Buy" rating by Raymond James given on Thursday, February 9.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Cowen & Co maintained Supernus Pharmaceuticals, Inc.

Since August 1, 2017, it had 0 insider buys, and 11 sales for $41.13 million activity. (NASDAQ:GILD) rating on Thursday, November 30. Alton Gregg H had sold 25,000 shares worth $2.07M. Over the last 90 days, insiders sold 461,666 shares of company stock worth $34,072,567. On Tuesday, January 2 the insider MARTIN JOHN C sold $3.68 million.

Investors sentiment increased to 1.53 in 2017 Q3. Its down 0.10, from 1.36 in 2017Q2. It is negative, as 22 investors sold SUPN shares while 97 reduced holdings.

Several other institutional investors and hedge funds have also recently made changes to their positions in GILD. 146.35 million shares or 1.92% less from 149.22 million shares in 2017Q2 were reported. Gofen Glossberg Limited Liability Il owns 243,048 shares for 0.73% of their portfolio. Ftb Advsrs has invested 0% in Supernus Pharmaceuticals, Inc. (NASDAQ:AMZN). Hilltop Hldg Incorporated holds 446 shares. 201,405 are owned by Victory Capital Management Inc. The stock has "Buy" rating by RBC Capital Markets on Tuesday, September 26. (NASDAQ:GILD) has "Mkt Perform" rating given on Tuesday, September 27 by Leerink Swann. Finally, Northern Trust Corp lifted its stake in shares of Gilead Sciences by 0.7% in the second quarter. (NASDAQ:AMZN) or 18,691 shares. 8,776 were reported by Terril Brothers. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.